In this study, we investigated the therapeutic efficacy of LAT1-targeted alpha therapy using a novel modified 3-astatin-211 Astato-α-methyl-L-tyrosine (211At-AAMT) for bone and soft tissue sarcomas. The gene discussed is SLC7A5; the disease is soft tissue sarcoma.